Danaher agrees to acquire US medical tech company Masimo for $9.9B, paying $180 per share, a nearly 40% premium on February 13's close, set to close in H2 2026
Danaher Corp. agreed to buy US medical technology firm Masimo Corp., in a deal with an enterprise value of about $9.9 billion.
Context & Ripple Effects
The agreement follows same-day reporting that Danaher was nearing a Masimo transaction, moving a reported deal into a defined offer with a stated closing window. Masimo enters the process while its pending acquisition discussions sit alongside an unresolved intellectual-property conflict involving Apple Watch.
It also joins a recent run of large acquisitions in scientific and life-sciences technology, including Siemens’s purchase of Dotmatics and Thermo Fisher’s deal for Clario. Those transactions make the Masimo deal a relevant test of continued appetite for scaled, specialized healthcare-technology assets.
First-order effects
- Masimo shareholders are offered $180 per share, transferring the stated premium directly to current holders if the transaction closes.
- Danaher gains control of Masimo after closing, while Masimo’s Apple-related IP matters become part of a larger owner’s portfolio rather than a standalone company’s agenda.
Second-order effects
- The nearly 40% premium establishes a fresh public-market reference point for comparable medtech targets and could sharpen pressure on prospective buyers to demonstrate strategic value in bids.
- Other healthcare and life-sciences acquirers face a more concentrated set of scaled platforms as Danaher adds Masimo, reinforcing competition for specialized assets rather than broadening the field of independent targets.
Third-order effects
- If comparable transactions continue to close, medtech and scientific-technology markets may increasingly be organized around large strategic owners assembling portfolios of specialized products and software.
- The deal also shows that IP exposure need not preclude consolidation, though the outcome of Masimo’s Apple-related disputes will determine how readily such issues can be absorbed in future transactions.
The trend: Large strategic buyers are continuing to concentrate specialized healthcare and life-sciences technology assets through high-value acquisitions.